A hybrid chimeric version of SARS-Cov-2 virus, which causes COVID-19, named VSV-SARS-CoV-2, was created in a lab in July of 2020. Ironically, the CDC recommends the use of face masks to stop the spread of COVID-19, yet they say they created VSV-SARS-CoV-2 because the wild virus SARS-CoV-2 is so incredibly contagious that the virologist need to wear full biohazard protection gear with pressurized respirators because of High Biosafety Level [BSL] conditions. We’re expected to be indoctrinated enough to believe the nonsensical notion that we’re protected enough to actually make a difference with a mask. Naturally, this causes doubt to be casted on the effectiveness of wearing face masks.
Washington University School of Medicine in St. Louis says in their Cell and Microbe study that they were able to use gene editing to, “generate a replication-competent vesicular stomatitis virus (VSV) expressing the SARS-CoV-2 spike and compare the neutralizing activity of antibodies with VSV-SARS-CoV-2 to fully infectious SARS-CoV-2. They show that VSV-SARSCoV-2 is a useful BSL2 surrogate virus, as neutralization profiles strongly correlate with focus-reduction neutralization tests using SARS-CoV-2.”
SARS-CoV-2 is a BSL3 virus, as opposed to the VSV-SARS-CoV-2 which is a BSL2 virus. This allows labs that don’t have the proper protective gear or laboratories that are not built to contain a BSL3, every lab is made to be able to handle BL2, in order to have more labs able to work on creating a effective antibody based vaccination for the prevention of COVID-19.
Washington University explained, “viruses have proteins on their surfaces that they use to latch onto and infect cells. The researchers removed VSV’s surface-protein gene and replaced it with the one from SARS-CoV-2, known as spike. The switch created a new virus that targets cells like SARS-CoV-2 but lacks the other genes needed to cause severe disease. They dubbed the hybrid virus VSV-SARS-CoV-2.”
There have been two research groups that have been able to demonstrate engineered llama antibodies are able to neutralize the wild SARS-CoV-2, which is a possible treatment that has the potential to treat severe COVID-19 patients. The scientists found that VSV-SARS-CoV-2 was able to infect the cells, and antibodies recognized the chimeric virus comparably to the wild virus, when testing it with convalescent serum and purified antibodies. A promising sign that labs will be able to be able to test if drugs will work as a treatment for the novel coronavirus that has spread throughout the world as well.